Skip to content

Clinical observation of Ruyi Zhenbao tablets in the treatment of residual symptoms after collagenase chemolysis for lumbar disc herniation

Clinical observation of Ruyi Zhenbao tablets in the treatment of residual symptoms after collagenase chemolysis for lumbar disc herniation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500101834
Enrollment
Unknown
Registered
2025-04-30
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc herniation

Interventions

Ruyi Zhenbao tablet group:Take Ruyi Zhenbao tablets after collagenase lysis
Mecobalamin+celecoxib capsule group:Taking Mecobalamin+celecoxib capsules after collagenase lysis

Sponsors

Shaoxing Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who came to Shaoxing second hospital and Zhuji Second People's hospital to see a doctor who met the requirements of lumbar disc herniation and underwent collagenase lysis

Exclusion criteria

Exclusion criteria: 1. The patient's symptoms do not meet the above diagnostic criteria and do not meet the corresponding inclusion criteria; 2. Combined with lumbar instability or spondylolisthesis, cauda equina syndrome, lumbar tuberculosis, tumor, infection; Identify patients with other causes of low back and leg pain; 3. Patients with other medical history such as cardiovascular and cerebrovascular, peripheral neuropathy, severe osteoporosis, bone tumor, etc.; 4. Those who have no residual symptoms such as low back and leg pain after surgery; 5. Those whose postoperative symptoms are not significantly relieved or even aggravated compared with before; 6. Multi-level intervertebral disc herniation; 7. Impairment of consciousness and psychiatric illness in the patient's medical history; 8. Patients who participate in other trials at the same time; 9. Patients who automatically discontinued the drug halfway and had poor compliance.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale, VAS;

Secondary

MeasureTime frame
Japanese Orthopaedic Association Scores,JOA;Oswestry disability index,ODI;

Countries

China

Contacts

Public ContactLu Cai

Shaoxing Second Hospital

cailu345@163.com+86 159 6758 8551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026